151. L-Glutamine Substantially Improves 5-Fluorouracil-Induced Intestinal Mucositis by Modulating Gut Microbiota and Maintaining the Integrity of the Gut Barrier in Mice.
- Author
-
Kuo YR, Lin CH, Lin WS, and Pan MH
- Subjects
- Animals, Mice, Inbred ICR, Male, Toll-Like Receptor 4 metabolism, NF-E2-Related Factor 2 metabolism, Dysbiosis chemically induced, Dysbiosis drug therapy, Mice, NF-kappa B metabolism, Oxidative Stress drug effects, TOR Serine-Threonine Kinases metabolism, Antimetabolites, Antineoplastic adverse effects, Heme Oxygenase-1 metabolism, Gastrointestinal Microbiome drug effects, Fluorouracil adverse effects, Glutamine pharmacology, Mucositis chemically induced, Mucositis drug therapy, Mucositis metabolism, Intestinal Mucosa drug effects, Intestinal Mucosa metabolism
- Abstract
Scope: This study investigates the potential of glutamine to mitigate intestinal mucositis and dysbiosis caused by the chemotherapeutic agent 5-fluorouracil (5-FU)., Methods and Results: Over twelve days, Institute of Cancer Research (ICR) mice are given low (0.5 mg kg
-1 ) or high (2 mg kg-1 ) doses of L-Glutamine daily, with 5-FU (50 mg kg-1 ) administered between days six and nine. Mice receiving only 5-FU exhibited weight loss, diarrhea, abnormal cell growth, and colonic inflammation, correlated with decreased mucin proteins, increased endotoxins, reduced fecal short-chain fatty acids, and altered gut microbiota. Glutamine supplementation counteracted these effects by inhibiting the Toll-like receptor 4/nuclear factor kappa B (TLR4/NF-κB) pathway, modulating nuclear factor erythroid 2-related factor 2/heme oxygenase 1 (Nrf2/HO-1) oxidative stress proteins, and increasing mammalian target of rapamycin (mTOR) levels, thereby enhancing microbial diversity and protecting intestinal mucosa., Conclusions: These findings underscore glutamine's potential in preventing 5-FU-induced mucositis by modulating gut microbiota and inflammation pathways., (© 2024 Wiley‐VCH GmbH.)- Published
- 2024
- Full Text
- View/download PDF